{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.66","upperLimit":"0.84","value":"0.76"}]}],"title":"Still Responder by 48 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.55","upperLimit":"0.76","value":"0.67"}]}],"title":"Still Responder by 96 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.02","upperLimit":"0.63","value":"0.27"}]}],"title":"Still Responder by 144 weeks"}],"denoms":[{"counts":[{"groupId":"OG000","value":"91"}],"units":"Participants"}],"description":"The maintenance of ≥ 35% reduction from Baseline in spleen volume was assessed up until the data cutoff date using the Kaplan-Meier method for patients who had at least one measured ≥ 35% reduction, and who either had at least one subsequent measurement or who subsequently dropped out prior to another assessment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants began treatment with ruxolitinib 15 or 20 mg taken orally twice a day based on Baseline platelet count. The dose was adjusted by the Investigator based on efficacy and safety to a maximum of 25 mg twice daily.","id":"OG000","title":"Ruxolitinib"}],"paramType":"NUMBER","populationDescription":"Patients who had at least 1 measurement of ≥ 35% reduction from Baseline in spleen volume at any time during the study and had at least 1 subsequent measurement or withdrew prior to another assessment.","reportingStatus":"POSTED","timeFrame":"Baseline Visit and every 12 weeks until the data cut-off date (up to 14 months).","title":"Maintenance of a ≥ 35% Reduction From Baseline in Spleen Volume Among Patients Initially Randomized to Receive Ruxolitinib","type":"SECONDARY","unitOfMeasure":"proportion of participants"}